Eli Lilly Terminates Study Of Bimagrumab In Obesity

2025-09-25 08:13:37

(MENAFN- AsiaNet News)

Eli Lilly & Co. (LLY) has halted the study of its drug Bimagrumab, alone or in combination with its approved weight-loss drug Tirzepatide, in patients with obesity.

A U.S. registry of clinical trials indicates that the study has been terminated due to strategic business reasons. The purpose of the study was to see how well and how safely Bimagrumab, Tirzepatide, and the combination worked in lowering body weight in participants with obesity or overweight and type 2 diabetes.

Bloomberg first reported the termination of the trial. Following the development, the stock traded 0.59% lower in Thursday's pre-market session.

Get updates to this developing story directly on Stocktwits.

MENAFN25092025007385015968ID1110110358

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.